| Autoimmune and Inflammatory Disorders Research | Lifetime | 30 | US 11 | 99.67 |
| Biosimilars and Bioanalytical Methods | Lifetime | 17 | US 4 | 99.41 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 55 | US 18 | 99.71 |
| Systemic Lupus Erythematosus Research | Lifetime | 81 | US 32 | 99.60 |
| Spondyloarthritis Studies and Treatments | Lifetime | 33 | US 8 | 99.49 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 87 | US 32 | 99.14 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 573 | US 319 | 99.02 |
| Lymphoma Diagnosis and Treatment | Lifetime | 446 | US 217 | 98.84 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 470 | US 219 | 98.70 |
| Inflammatory mediators and NSAID effects | Lifetime | 430 | US 206 | 97.47 |
| Pharmacological Effects of Natural Compounds | Lifetime | 692 | US 104 | 95.94 |
| Systemic Sclerosis and Related Diseases | Lifetime | 448 | US 139 | 96.81 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 817 | US 360 | 96.11 |
| Osteoarthritis Treatment and Mechanisms | Lifetime | 967 | US 342 | 96.18 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 385 | US 124 | 93.46 |
| Fibromyalgia and Chronic Fatigue Syndrome Research | Lifetime | 805 | US 260 | 94.12 |
| Peripheral Neuropathies and Disorders | Lifetime | 772 | US 221 | 94.79 |
| Musculoskeletal synovial abnormalities and treatments | Lifetime | 827 | US 336 | 91.68 |
| Case Reports on Hematomas | Lifetime | 471 | US 167 | 79.17 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 92 | US 23 | 97.56 |
| Spondyloarthritis Studies and Treatments | 2021-2025 | 64 | US 13 | 97.78 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 132 | US 30 | 97.73 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 251 | US 61 | 96.43 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 172 | US 31 | 96.47 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 311 | US 124 | 87.13 |
| Fibromyalgia and Chronic Fatigue Syndrome Research | 2021-2025 | 603 | US 132 | 83.43 |
| Urticaria and Related Conditions | 2021-2025 | 468 | US 85 | 85.08 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 387 | US 78 | 78.17 |
| Musculoskeletal Disorders and Rehabilitation | 2021-2025 | 675 | US 198 | 49.45 |
